Kiran Mazumdar Shaw, chairperson and managing director, Biocon said we are confident of clocking sales of over $200 million for biologics in FY19.

Shaw said that Mylan-Biocon launched biosimilar pegfilgrastim in the US.

Talking about trastuzumab, she said, “The US approval has been obtained and Mylan is in preparation to launch it when it is possible because they have an agreement with Roche for launching of this product in the US and in Europe.”

She further said that our dossier for trastuzumab under review by the EU authorities.

“We expect to enter into the European Union and Australia by the end of this calendar year,” she further mentioned.

"R&D costs have come down to Rs 88 crore this quarter," she added.

She also said that the decisions on Lupin tie-up was a commercial decision